The cost of specialty medications is rising faster than any other component of health care. This is driven largely by biologic medications for inflammatory conditions and new treatments for cancer and rare diseases. Biosimilars are comparable to biologic medications ad offer potential savings for patients.

Cigna Healthcare^SM regularly evaluates biosimilars to determine which are appropriate for our pharmacy benefit manager formularies. When assessing a biosimilar, we consider many factors, including:

• Clinical safety.
• Efficacy data.
• Indications approved by the U.S. Food and Drug Administration.
• The ability of the biosimilar to meet market demand.

Our approach to HUMIRA and alternative biosimilars

We offer HUMIRA^® and select HUMIRA biosimilars on Cigna Pharmacy Management^® preferred prescription drug lists. By including certain biosimilars on our preferred drug lists along with HUMIRA, we are able to:

• Expand choice and drive affordability for anti-inflammatory drugs, the costliest therapeutic class.
• Demonstrate our long-standing support and advancement of biosimilars as a pathway to more choices for providers and customers.
• Increase access to life-changing specialty medications.
• Potentially lower health care costs.

No out-of-pocket cost for biosimilar through Accredo

Beginning in June, Accredo by Evernorth^® will offer a HUMIRA biosimilar to eligible Cigna Healthcare customers at $0 out-of-pocket cost. The high- and low-concentration interchangeable biosimilar is estimated to save each patient an average of $3,500 per year.

For more information, please refer to the press release on the Evernorth website.